SCHEMBL14959680

SCHEMBL14959680

CCc1ccc(C(=O)NCCCOC)nc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 2/20 0.46
HTT P42858 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HPGDS O60760 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
GAA P10253 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
TP53 P04637 1/20 0.44
LMNA P02545 1/20 0.44
MAOB P27338 1/20 0.43
RECQL P46063 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MKNK1 Q9BUB5 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18873904 0.85 ALDH1A1 (0.49) ALDH1A1KDM4EHTTKDM4CL3MBTL1
SCHEMBL9561573 0.83 ALDH1A1 (0.69) ALDH1A1KDM4EHTTKDM4CL3MBTL1
SCHEMBL9908372 0.81 PARP1 (0.53) ALDH1A1KDM4EL3MBTL1SMN1; SMN2MEN1
SCHEMBL7883731 0.77 MAPK1 (0.62) ALDH1A1KDM4EL3MBTL1SMN1; SMN2MEN1
SCHEMBL12561176 0.76 PLK1 (0.55) ALDH1A1KDM4EL3MBTL1SMN1; SMN2MEN1
SCHEMBL12895235 0.75 ALDH1A1 (0.74) ALDH1A1KDM4EHTTKDM4CL3MBTL1
SCHEMBL12601105 0.75 HIF1A (0.51) ALDH1A1KDM4EL3MBTL1MEN1KMT2A
SCHEMBL18665453 0.75 CHRM2 (0.52) ALDH1A1KDM4EHTTL3MBTL1SMN1; SMN2
SCHEMBL25737802 0.74 LOXL2 (0.50) ALDH1A1KDM4EL3MBTL1SMN1; SMN2MEN1
SCHEMBL27308715 0.74 MAPT (0.49) ALDH1A1KDM4EL3MBTL1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160272577-A1 ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2016-09-22 US disclosed
US-9328071-B2 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2016-05-03 US disclosed
US-20140309264-A1 ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2014-10-16 US disclosed
US-8802720-B2 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2014-08-12 US disclosed
US-20130225605-A1 ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2013-08-29 US disclosed
US-8445530-B2 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2013-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272577-A1 ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS EDF1, LPAR2, LIPG ALDH1A1 2149/4885KDM4E 938/4885HTT 4545/4885
US-20130225605-A1 ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS EDF1, LPAR2, LIPG ALDH1A1 2149/4885KDM4E 938/4885HTT 4545/4885
US-20140309264-A1 ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS EDF1, LPAR2, LIPG ALDH1A1 2149/4885KDM4E 938/4885HTT 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.